ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Warszawa, Mazowieckie, POL:

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 2, Phase 3

Immunocore
Immunocore

Warsaw, Poland and 70 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Warszawa, Poland and 227 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Warszawa, Poland and 154 other locations

medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...

Enrolling
Melanoma
Drug: encorafenib
Drug: ipilimumab

Phase 2

Pfizer
Pfizer

Warszawa, Poland and 62 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Warsaw, Poland and 55 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Drug: Ceralasertib
Biological: Durvalumab

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 63 other locations

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Warsaw, Poland and 64 other locations

with previously untreated unresectable or metastatic (advanced) melanoma.Patients will be stratified on the basis of the following factors; ...

Active, not recruiting
Unresectable Melanoma
Metastatic Melanoma
Drug: IO102-IO103
Drug: Pembrolizumab

Phase 3

IO Biotech

Warsaw, Masovian, Poland and 111 other locations

patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...

Active, not recruiting
Melanoma Stage IV
Melanoma Stage III
Biological: BNT111
Biological: Cemiplimab

Phase 2

BioNTech
BioNTech

Warsaw, Poland and 52 other locations

(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...

Active, not recruiting
Melanoma
Drug: Trametinib
Drug: Dabrafenib

Phase 3

Novartis
Novartis

Warszawa, Poland and 178 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems